141 related articles for article (PubMed ID: 38612819)
1. Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer.
Muniz IAF; Araujo M; Bouassaly J; Farshadi F; Atique M; Esfahani K; Bonan PRF; Hier M; Mascarella M; Mlynarek A; Alaoui-Jamali M; Silva SDD
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612819
[TBL] [Abstract][Full Text] [Related]
2. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
3. The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma.
Fung N; Faraji F; Kang H; Fakhry C
Cancer Metastasis Rev; 2017 Sep; 36(3):449-461. PubMed ID: 28812214
[TBL] [Abstract][Full Text] [Related]
4. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
5. De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research.
Petar S; Marko S; Ivica L
Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4599-4603. PubMed ID: 33599841
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival.
Lee HI; Lee J; Lee JH; Wu HG; Kim JH; Kim Y; Eom KY
JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1059-1067. PubMed ID: 36173618
[TBL] [Abstract][Full Text] [Related]
7. Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma.
Atique M; Muniz I; Farshadi F; Hier M; Mlynarek A; Macarella M; Maschietto M; Nicolau B; Alaoui-Jamali MA; da Silva SD
Biomedicines; 2023 Dec; 12(1):. PubMed ID: 38275384
[TBL] [Abstract][Full Text] [Related]
8. Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma.
Navran A; Al-Mamgani A; Elzinga H; Kessels R; Vens C; Tesselaar M; van den Brekel M; de Haan R; van Triest B; Verheij M
Clin Transl Radiat Oncol; 2024 Jan; 44():100698. PubMed ID: 38021094
[TBL] [Abstract][Full Text] [Related]
9. A Phase I Study of the CDK4/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Ngamphaiboon N; Pattaranutaporn P; Lukerak S; Siripoon T; Jinawath A; Arsa L; Shantavasinkul PC; Taonam N; Trachu N; Jinawath N; Kositwattanarerk A; Sananmuang T; Jiarpinitnun C
Clin Cancer Res; 2024 Jan; 30(2):294-303. PubMed ID: 37982827
[TBL] [Abstract][Full Text] [Related]
10. RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trapping.
Zamalloa LG; Pruitt MM; Hermance NM; Gali H; Flynn RL; Manning AL
Life Sci Alliance; 2023 Dec; 6(12):. PubMed ID: 37704395
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain‑of‑function and targeting therapy (Review).
Li M; Sun D; Song N; Chen X; Zhang X; Zheng W; Yu Y; Han C
Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37449494
[TBL] [Abstract][Full Text] [Related]
12. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Tao Y; Sun XS; Pointreau Y; Le Tourneau C; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Calderon B; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Damstrup L; Crompton P; Ennaji A; Gollmer K; Nauwelaerts H; Bourhis J
Eur J Cancer; 2023 Apr; 183():24-37. PubMed ID: 36796234
[TBL] [Abstract][Full Text] [Related]
13. MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers.
Gurbi B; Brauswetter D; Pénzes K; Varga A; Krenács T; Dános K; Birtalan E; Tamás L; Csala M
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769112
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
